Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy
JACC: Advances · 2026-12 · 5 (12) · 103458
DOI: 10.1016/j.jacadv.2026.103458 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2026-12. Verfasst von Daniel J Friedman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Electrophysiology Section, Duke University Hospital, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. Elec…. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boston Scientific Corp.
Abstract (Originalsprache)
BACKGROUND: Although Watchman left atrial appendage occlusion (LAAO) was approved for patients with atrial fibrillation who can tolerate short term anticoagulation, many patients are poor candidates for any duration of anticoagulation. OBJECTIVES: The objective of the study was to compare 1-year outcomes among patients receiving Watchman LAAO vs antiplatelet monotherapy. METHODS: We performed an overlap weighted observational comparative effectiveness analysis of postdischarge outcomes among Medicare beneficiaries in the Get With The Guidelines-AFIB Registry who received LAAO or antiplatelet therapy. Cox Regression was used for all-cause mortality and cause-specific hazard models were used for nonfatal outcomes. A win ratio was calculated with the following endpoint hierarchy: 1) all-cause death; 2) stroke, systemic embolism, or transient ischemic attack (TIA); 3) major bleeding (excluding gastrointestinal bleeding); and 4) gastrointestinal bleeding. RESULTS: -VASC score 5). Through the first 45 days, the adjusted risk of stroke, TIA or systemic embolism, major bleeding, or death was lower among patients who received LAAO (HR: 0.26; CI: 0.17-0.41; P < 0.001). Between 46 days and 1 year, the risk for the composite outcome was lower among patients who received LAAO (HR: 0.61; CI: 0.48-0.78; P < 0.001). The win ratio at 1 year was 2.71 (95% CI: 1.92-3.83; P < 0.0001), indicating significantly better outcomes among LAAO patients. CONCLUSIONS: Among patients with atrial fibrillation, treatment with LAAO was associated with a lower risk of stroke, TIA or systemic embolism, major bleeding, or death compared to antiplatelet therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Electrophysiology Section, Duke University Hospital, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: daniel.friedman@duke.edu.
- Duke Clinical Research Institute, Durham, North Carolina, USA.
- Division of Cardiology, Virginia Commonwealth University, Richmond, Virginia, USA.
- Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
- Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina USA.
- Electrophysiology Section, Duke University Hospital, Durham, North Carolina, USA.
Förderung
- Boston Scientific Corp
Zitieren
APA
Friedman, D. J., Ayodele, I., Holmes, D., Alhanti, B., Ellenbogen, K. A., Fonarow, G. C., Kent, A. P., Jackson, K. P., Joglar, J. A., Lewis, W. R., Russo, A. M., Vemulapali, S., & Piccini, J. P. (2026). Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy. JACC: Advances, 5(12), 103458. https://doi.org/10.1016/j.jacadv.2026.103458
Vancouver
Friedman DJ, Ayodele I, Holmes D, Alhanti B, Ellenbogen KA, Fonarow GC, et al. Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy. JACC: Advances. 2026;5(12):103458. doi:10.1016/j.jacadv.2026.103458
BibTeX
@article{Friedman2026,
author = {Friedman, Daniel J and Ayodele, Iyanuoluwa and Holmes, DaJuanicia and Alhanti, Brooke and Ellenbogen, Kenneth A and Fonarow, Gregg C and Kent, Anthony P and Jackson, Kevin P and Joglar, Jose A and Lewis, William R and Russo, Andrea M and Vemulapali, Sreek and Piccini, Jonathan P},
title = {Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy},
journal = {JACC: Advances},
year = {2026},
volume = {5},
number = {12},
pages = {103458},
doi = {10.1016/j.jacadv.2026.103458}
}
EUVIMED